Aikaterini Chatzipli
Aikaterini Chatzipli, PhD
Research Fellow in Biomedical Informatics, Harvard Medical School
Mentor: Peter Park, PhD

Aikaterini Chatzipli received her PhD in Genetics from Churchill College at Cambridge University. After completing her PhD, Chatzipli joined the Wellcome Sanger Institute as a Postdoctoral Fellow, where she worked on a variety of projects exploring the utility of large DNA sequencing studies (S:CORT Consortium, PDX Finder) to predict clinical outcomes for cancer patients and shed light on tumor evolution of different cancers (Draaisma, Chatzipli et al., Journal of Clinical Oncology, 2019). Her work also involved modeling chromosomal catastrophes (e.g., chromothripsis) often seen in cancer, and unraveling of their mechanisms (Maciejowski, Chatzipli, et al., Nature Genetics, 2020). Apart from research, Chatzipli also enjoyed teaching Cell Biology modules to undergraduate Natural Sciences students as part of her Fitzwilliam College Bye-Fellowship at Cambridge University

In the Park Lab, Chatzipli works on genome-scale sequencing data to generate insights on the molecular mechanisms underlying cancer and rare human diseases as part of the GeM Consortium and Undiagnosed Diseases Network

In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer.
Authors: Malla SB, Fisher DJ, Domingo E, Blake A, Hassanieh S, Redmond KL, Richman SD, Youdell M, Walker SM, Logan GE, Chatzipli A, Amirkhah R, Humphries MP, Craig SG, McDermott U, Seymour MT, Morton DG, Quirke P, West NP, Salto-Tellez M, Kennedy RD, Johnston PG, Tomlinson I, Koelzer VH, Campo L, Kaplan RS, Longley DB, Lawler M, Maughan TS, Brown LC, Dunne PD.
Clin Cancer Res
View full abstract on Pubmed
APOBEC3-dependent kataegis and TREX1-driven chromothripsis during telomere crisis.
Authors: Maciejowski J, Chatzipli A, Dananberg A, Chu K, Toufektchan E, Klimczak LJ, Gordenin DA, Campbell PJ, de Lange T.
Nat Genet
View full abstract on Pubmed
Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning.
Authors: Sirinukunwattana K, Domingo E, Richman SD, Redmond KL, Blake A, Verrill C, Leedham SJ, Chatzipli A, Hardy C, Whalley CM, Wu CH, Beggs AD, McDermott U, Dunne PD, Meade A, Walker SM, Murray GI, Samuel L, Seymour M, Tomlinson I, Quirke P, Maughan T, Rittscher J, Koelzer VH.
View full abstract on Pubmed
Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study.
Authors: Draaisma K, Chatzipli A, Taphoorn M, Kerkhof M, Weyerbrock A, Sanson M, Hoeben A, Lukacova S, Lombardi G, Leenstra S, Hanse M, Fleischeuer R, Watts C, McAbee J, Angelopoulos N, Gorlia T, Golfinopoulos V, Kros JM, Verhaak RGW, Bours V, van den Bent MJ, McDermott U, Robe PA, French PJ.
J Clin Oncol
View full abstract on Pubmed
PDX Finder: A portal for patient-derived tumor xenograft model discovery.
Authors: Conte N, Mason JC, Halmagyi C, Neuhauser S, Mosaku A, Yordanova G, Chatzipli A, Begley DA, Krupke DM, Parkinson H, Meehan TF, Bult CC.
Nucleic Acids Res
View full abstract on Pubmed
Roles of cofactors and chromatin accessibility in Hox protein target specificity.
Authors: Beh CY, El-Sharnouby S, Chatzipli A, Russell S, Choo SW, White R.
Epigenetics Chromatin
View full abstract on Pubmed